7 crispr stocks to watch

Considering investing in crispr stocks? While the best crispr stocks depend on your portfolio and investment goals, we've identified some crispr stocks that are worth keeping an eye on in the gene editing sector. Keep reading to learn more about crispr stocks and how to start investing.

7 popular crispr stocks to watch

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap stocks.

Best stock	1-year return	Market cap	Exchange	Volume	Buy now on CIBC Investor's Edge
Crispr Therapeutics (CRSP.US)	13.09% Crispr Therapeutics's 1-year return based on the closing price as of December 5, 2024.	$5.1 billion (USD)	NASDAQ	1,948,883	Buy now
Editas Medicine (EDIT.US)	14.66% Editas Medicine's 1-year return based on the closing price as of December 5, 2024.	$230.9 million (USD)	NASDAQ	1,681,446	Buy now
Regeneron Pharmaceuticals (REGN.US)	-5.76% Regeneron Pharmaceuticals's 1-year return based on the closing price as of December 5, 2024.	$82.7 billion (USD)	NASDAQ	1,238,500	Buy now
Cellectis (CLLS.US)	135.35% Cellectis's 1-year return based on the closing price as of December 5, 2024.	$526.3 million (USD)	NASDAQ	52,670	Buy now
Beam Therapeutics Inc (BEAM.US)	5.61% Beam Therapeutics Inc's 1-year return based on the closing price as of December 5, 2024.	$2.6 billion (USD)	NASDAQ	2,662,649	Buy now
Bluebird bio (BLUE.US)	(data unavailable)	$48.7 million (USD)	NASDAQ	(data unavailable)	Buy now
Sangamo Therapeutics (SGMO.US)	(data unavailable)	$143.1 million (USD)	NASDAQ	(data unavailable)	Buy now

The values in this table are accurate as of the market close on December 4, 2025, or the most recent data available. Volume refers to the number of shares traded during the day.

What to look for when investing in crispr stock

The gene editing industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering crispr stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.

Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.

How to invest in crispr stock

1. Research the gene editing industry. Before investing, learn about the crispr stock sector, its trends and the companies within it. Look at each company's financial health, potential for growth and past performance to identify stocks that fit your investment goals.
2. Choose a stock trading platform. Compare trading fees, access to trading tools and user interface options. We've identified reliable trading platforms to help narrow down your options below or check out the best stock trading apps in Canada to find one that suits your needs.
3. Open and fund your account. Sign up with your personal details and link a bank account or funding method to deposit money before you start trading.
4. Select the crispr stock(s) to buy. Search by company name or ticker symbol, like CRSP or EDIT. Compare key metrics such as market cap, price history and earnings per share to pick the best stock for your strategy.
5. Buy the stock and monitor performance. Place your order to buy the stock and track its performance over time. Consider setting alerts, signing up for industry newsletters or using platform research tools to stay up to date on market changes.

Our top picks for where to buy crispr stocks

Are crispr stocks a good investment?

While it's possible to turn a profit investing in crispr stocks, keep in mind that—like any investment—crispr stocks are not immune to risk. These stocks are subject to fluctuating conditions both in the market and in the gene editing industry, so carefully vet your picks before you invest.

What are the best crispr stocks?

A lot of factors go into picking the best crispr stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong crispr stock investment for one person might not be suitable for another.

That said, we rounded up this list of popular crispr stocks in or related to the gene editing industry to help narrow down your options:

• Crispr Therapeutics (CRSP)
• Editas Medicine (EDIT)
• Regeneron Pharmaceuticals (REGN)
• Cellectis (CLLS)
• Beam Therapeutics Inc (BEAM)
• Bluebird bio (BLUE)
• Sangamo Therapeutics (SGMO)

Keep in mind that this is not a "best" list or a recommendation. It highlights some crispr stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.

We've outlined detailed company and stock performance details for each crispr stock below. Keep reading to decide if any of these companies are the right investment for you.

---

Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.

Closing stock price	$55.99
Market Capitalization The total market value of Crispr Therapeutics's outstanding shares	$5.1 billion
Gross profit (TTM)	$-430,665,984
Revenue (TTM)	$38.3 million
Earnings per share (TTM)	-$5.54
52-week stock price range	$30.04 – $78.48

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 2, 2025.

---

Editas Medicine (EDIT)

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Closing stock price	$2.19
Market Capitalization The total market value of Editas Medicine's outstanding shares	$230.9 million
Gross profit (TTM)	$-64,777,000
Revenue (TTM)	$46.4 million
Earnings per share (TTM)	-$2.35
52-week stock price range	$0.91 – $4.54

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 30, 2025.

---

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Closing stock price	$723.67
Market Capitalization The total market value of Regeneron Pharmaceuticals's outstanding shares	$82.7 billion
Gross profit (TTM)	$6.5 billion
Profit margin	32.13%
Revenue (TTM)	$14.2 billion
Earnings per share (TTM)	$41.74
52-week stock price range	$475.17 – $796.57

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 2, 2025.

---

Cellectis (CLLS)

Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Closing stock price	$4.66
Market Capitalization The total market value of Cellectis's outstanding shares	$526.3 million
Gross profit (TTM)	$82.6 million
Profit margin	-42.83%
Revenue (TTM)	$82.6 million
Earnings per share (TTM)	-$0.33
52-week stock price range	$1.10 – $5.48

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 2, 2025.

---

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

Closing stock price	$26.74
Market Capitalization The total market value of Beam Therapeutics Inc's outstanding shares	$2.6 billion
Gross profit (TTM)	$-356,086,016
Revenue (TTM)	$55.7 million
Earnings per share (TTM)	-$4.41
52-week stock price range	$13.53 – $35.25

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 2, 2025.

---

Bluebird bio (BLUE)

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Market Capitalization The total market value of Bluebird bio's outstanding shares	$48.7 million
Gross profit (TTM)	$28.2 million
Profit margin	-192.39%
Revenue (TTM)	$103.9 million
Earnings per share (TTM)	-$20.59
52-week stock price range	$3.20 – $15.40

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 4, 2025.

---

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A.

Market Capitalization The total market value of Sangamo Therapeutics's outstanding shares	$143.1 million
Gross profit (TTM)	$-72,032,000
Revenue (TTM)	$32.9 million
Earnings per share (TTM)	-$0.45
52-week stock price range	$0.38 – $2.84

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 4, 2025.

Compare trading platforms to buy CRISPR stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Bottom line

If you're considering adding crispr stocks to your portfolio, make sure you thoroughly look into any companies before investing to help mitigate risk. We've compiled a list of crispr stocks to help narrow down your options. Then choose a legitimate stock trading platform to start investing. After that it comes down to monitoring the gene editing industry to know when to buy, sell or hold.

Related: How to buy stocks in Canada

Frequently asked questions about crispr stocks

• What are crispr stocks?

  Crispr stocks are shares of companies that either directly work in the crispr sector or operate within related industries. Investors interested in buying crispr stocks may be looking to take advantage of market trends or lock in investments for the long haul.

• What is the top crispr stock to buy in 2025?

  Unfortunately, it's almost impossible to choose a single "top" crispr stock to invest in due to factors like market fluctuations, company management and shifting economic trends. These can all change—sometimes overnight—how a stock performs. It's best to do your own research to decide which companies fit within your risk tolerance. Reviewing a company's financial reports and past stock performance can help you decide if it's worth investing in.

• Where can I find information and regular updates about the gene editing industry?

  You can keep track of the latest gene editing news and updates by signing up for financial newsletters, visiting financial news sites, reading company investor relations pages and using market research platforms. Many online brokerages also offer sector reports, stock screeners and alerts to help you track movements in your stock performance or updates in or related to the gene editing industry.

Check these other commodities and investment sectors

If you're thinking about diversifying your portfolio and investing in sectors beyond crispr stocks, here are some others you can consider:

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.